Delivery Order SPE2DB22D3301-SPE2DB25FZ0SJ
- Not listed
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Ondansetron ODT 4 mg tablets (30-count) valued at $4,536.73 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 24, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price contract with a ceiling value of $1,821.89 and an ultimate completion date of July 25, 2025. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,181.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This competitive, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order represents a routine pharmaceutical procurement...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency for Ondansetron ODT 4 mg tablets (30-count supply) valued at $4,396.53 with a firm fixed price structure. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside competitive award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $13.45K to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999.99M ceiling value and extends...
- The U.S. government's Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $5,612.18 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,563,401,649 units of ondansetron ODT 8 mg tablets. The contract has an ultimate completion date of January 23, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $28,723.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive award to the pharmaceutical distributor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is part of...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,577.14 firm fixed-price delivery order is for the supply of 4560726475 Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of April 27, 2023 and was awarded on April 26, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,693.62 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0SJDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,793.24 by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and was competitively awarded with no set-aside designation. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a child contract under the prime IDC vehicle, this delivery order reflects AmerisourceBergen's critical role in the federal medical supply chain, particularly for the Defense Health Agency and other government healthcare systems. The company's portfolio demonstrates extensive capabilities in providing both brand-name and generic medications across multiple therapeutic domains, including specialty pharmaceuticals, vaccines, and medical devices. DLA Troop Support is currently planning next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards anticipated, underscoring the strategic importance of reliable pharmaceutical distribution to support military readiness and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/9/25 |